Nano drug delivery system based on natural cells and derivatives for ischemic stroke treatment.
10.1097/CM9.0000000000003685
- Author:
Wei LV
1
;
Yijiao LIU
2
;
Shengnan LI
3
;
Kewei REN
4
;
Hufeng FANG
5
;
Hua CHEN
6
;
Hongliang XIN
3
Author Information
1. Department of Pharmacy, The Jiangyin Clinical College of Xuzhou Medical University, Wuxi, Jiangsu 214499, China.
2. Department of Oncology, The Jiangyin Clinical College of Xuzhou Medical University, Wuxi, Jiangsu 214499, China.
3. Department of Pharmaceutics, Pharmacy School of Nanjing Medical University, Nanjing, Jiangsu 211166, China.
4. Department of Orthopedics, The Jiangyin Clinical College of Xuzhou Medical University, Wuxi, Jiangsu 214499, China.
5. Department of Pharmacy, The Third Affiliated Hospital of Nanjing Medical University, Changzhou Second People's Hospital, Changzhou, Jiangsu 213100, China.
6. Department of Neurosurgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu 210029, China.
- Publication Type:Review
- Keywords:
Blood-brain barrier;
Cell membrane biomimetic;
Drug delivery systems;
Engineering technology;
Ischemic stroke;
Natural cells and derivatives
- MeSH:
Humans;
Drug Delivery Systems/methods*;
Ischemic Stroke/drug therapy*;
Animals;
Blood-Brain Barrier/metabolism*;
Stroke/drug therapy*
- From:
Chinese Medical Journal
2025;138(16):1945-1960
- CountryChina
- Language:English
-
Abstract:
Ischemic stroke (IS) ranks as a leading cause of death and disability globally. The blood-brain barrier (BBB) poses significant challenges for effective drug delivery to brain tissues. Recent decades have seen the development of targeted nanomedicine and biomimetic technologies, sparking substantial interest in biomimetic drug delivery systems for treating IS. These systems are devised by utilizing or replicating natural cells and their derivatives, offering promising new pathways for detection and transport across the BBB. Their multifunctionality and high biocompatibility make them effective treatment options for IS. In addition, the incorporation of engineering techniques has provided these biomimetic drug delivery systems with active targeting capabilities, enhancing the accumulation of therapeutic agents in ischemic tissues and specific cell types. This improvement boosts drug transport and therapeutic efficacy. However, it is crucial to thoroughly understand the advantages and limitations of various engineering strategies employed in constructing biomimetic delivery systems. Selecting appropriate construction methods based on the characteristics of the disease is vital to achieving optimal treatment outcomes. This review summarizes recent advancements in three types of engineered biomimetic drug delivery systems, developed from natural cells and their derivatives, for treating IS. It also discusses their effectiveness in application and potential challenges in future clinical translation.
